News & Media
ImmunoQure AG announces the recovery of ownership and control of the IQ004 anti-Interferon-α antibody program following termination of the strategic partnership with Servier
ImmunoQure AG, a biotechnology company developing autoantibodies as therapeutics to treat human diseases today announced the termination of its strategic partnership with Servier
ImmunoQure AG and Memo Therapeutics AG announce collaboration for the production of APS-1 cognate, paired libraries
ImmunoQure AG and Memo Therapeutics AG, today announced an extended collaboration for the creation of cognate, paired heavy-light chain autoantibody libraries from APS-1 patients.
Servier and ImmunoQure AG enter into strategic partnership for the development of an Interferon-α human autoantibody
ImmunoQure, a biotech company focused on the research and development of human autoantibodies as therapeutics for the treatment of common human diseases and the international pharmaceutical company Servier today announced the establishment of a Worldwide, exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon- α.